What Is a Liver Stent for Cancer and What to Expect?

A “liver stent” for cancer is almost always a biliary stent, a small tube placed inside a bile duct to hold it open when a tumor is squeezing it shut. The bile ducts are the plumbing that carries bile from your liver to your intestines, and cancers of the pancreas, bile duct, or surrounding tissues frequently block that flow. The resulting backup of bile causes jaundice, itching, nausea, and a cascade of problems that can derail cancer treatment. Placing a stent restores drainage, and for many patients, the relief is substantial and relatively quick. But “what to expect” covers a lot of ground, from which stent type your doctor might choose to how long it takes to feel better and what happens if the stent eventually clogs.

Why Cancer Blocks the Bile Ducts

Bile is made by the liver, stored in the gallbladder, and released through a network of ducts into the small intestine, where it helps digest fats. Several types of cancer can obstruct this system. Pancreatic adenocarcinoma is the most common culprit, because the head of the pancreas sits right next to the common bile duct. Cholangiocarcinoma (bile duct cancer) grows directly in the duct walls. Gallbladder cancer, liver metastases, and even enlarged lymph nodes from other cancers can press on the ducts from the outside.¹

When bile cannot flow, bilirubin (the yellow pigment bile carries away) builds up in the blood. That is what turns the skin and eyes yellow. Beyond the visible jaundice, the obstruction causes intense itching, dark urine, pale stools, poor appetite, and fat malabsorption. Left untreated, the stagnant bile also invites infection (cholangitis), and in the long run, ongoing obstruction can damage the liver itself.²

The Goals of Biliary Stenting

For some patients, a stent is placed before surgery to bring bilirubin levels down so the operation can proceed more safely. For many others, especially those with advanced cancer, the stent is the treatment for the obstruction itself. The goals in that setting are straightforward: relieve symptoms, improve quality of life, prevent life-threatening infections, and keep the patient well enough to receive chemotherapy if that is part of the plan.³

Stenting is not a cure for the underlying cancer. It is a way of managing one of cancer’s most disruptive consequences. That distinction matters because it sets realistic expectations: the stent addresses the blockage and everything that flows from it, but the cancer itself still needs its own treatment strategy.

Plastic Stents vs. Metal Stents

Two broad categories of biliary stents exist, and the choice between them has real consequences for how long the stent stays open, how often you might need a repeat procedure, and overall cost.

Plastic stents are cheaper upfront, thinner, and easier to exchange. They have been used for decades. Their drawback is durability: they tend to clog faster, with one study reporting a median patency of roughly ten weeks compared to over twenty weeks for metal stents.⁴ That shorter lifespan means more trips back for re-intervention, more hospital days, and, for patients who survive beyond a couple of months, total costs that can actually match or exceed the cost of a metal stent placed once.

Self-expandable metal stents (SEMS) are delivered in a compressed form and spring open once positioned. They have a wider bore, which keeps bile flowing longer. A meta-analysis comparing the two found that metal stents stayed open significantly longer, required fewer repeat procedures, and were even associated with longer patient survival.⁵ For patients expected to live more than a few months, metal stents are generally the preferred choice. Plastic stents still make sense in certain situations, such as when surgery is planned soon and the stent only needs to last a few weeks, or when the diagnosis is still uncertain and doctors want an easily removable option.

Covered vs. Uncovered Metal Stents

Within the metal-stent family, there is a further design question: should the mesh be covered with a membrane, or left bare? The membrane on a covered stent blocks tumor tissue from growing through the gaps in the wire mesh, a problem called tumor ingrowth. One randomized trial found that tumor ingrowth occurred in none of the patients who received covered stents, compared with 15 patients in the uncovered group. Stent occlusion rates were about 14% for covered stents versus 38% for uncovered ones.⁶

That sounds like a clear win for covered stents, but they come with trade-offs. The membrane can irritate nearby structures, and the same trial noted higher rates of acute cholecystitis and mild pancreatitis in the covered group. A meta-analysis found that while covered stents had fewer adverse events overall, there was no significant difference in overall survival or primary stent patency between the two designs.⁷ One practical advantage of covered stents is that they can be removed or repositioned more easily, which matters if the stent migrates or if plans change.⁸

Your doctor’s recommendation will depend on where exactly the blockage sits, the type of tumor, and whether the stent needs to cross the opening of the cystic duct (which can raise the risk of gallbladder complications with a covered design).

How the Stent Gets Placed

Three main approaches exist for getting a stent into a bile duct, and understanding them can help demystify what your procedure day will look like.

ERCP (Through the Mouth)

Endoscopic retrograde cholangiopancreatography is the most common route. A flexible scope is passed through your mouth, down through the stomach, and into the upper part of the small intestine where the bile duct empties. The doctor threads the stent into the duct under X-ray guidance. Success rates for placing a stent below the liver hilum (where the main ducts branch) are above 90% across multiple international guidelines.⁹ You will be sedated for the procedure and will not eat for at least six hours beforehand. Most people do not remember much of it.

Percutaneous Transhepatic Drainage (Through the Skin)

When ERCP fails or is not feasible, an interventional radiologist can access the bile ducts by inserting a needle through the skin of the abdomen directly into the liver. This percutaneous approach is often used when the blockage is high up in the biliary tree (near the liver hilum), when prior surgery has altered the anatomy, or when an endoscopic attempt did not achieve adequate drainage.¹⁰ It can involve an external drain (a tube that exits through the skin into a bag) that may later be converted to an internal stent. This route requires sedation and carries its own set of comfort considerations during recovery, as the drain site needs care.

EUS-Guided Drainage (Ultrasound-Guided)

Endoscopic ultrasound-guided biliary drainage is a newer technique that uses an ultrasound-equipped scope to create a new connection between the bile duct or gallbladder and the stomach or intestine, then place a stent through it. It has emerged as an alternative when ERCP fails, and a randomized trial in pancreatic cancer patients found that EUS-guided drainage achieved comparable success rates to ERCP, with similar rates of technical success (about 91% vs 94%) and similar need for re-intervention.¹¹ EUS-guided approaches are becoming more common but are still mainly available at specialized centers.¹²

How Quickly Symptoms Improve

One of the first questions patients ask after stenting is “when will I feel better?” Bilirubin levels typically start dropping within days. A recent study found that about 80% of patients achieved at least a 50% reduction in bilirubin by day seven after endoscopic drainage, and roughly 70% reached a bilirubin level below 3 mg/dL by day fifteen.¹³

How fast your bilirubin normalizes depends heavily on how high it was before the stent went in. Patients whose pre-stent bilirubin was under 10 mg/dL saw 80% normalization within about three weeks. For those starting above 10 mg/dL, that same milestone took closer to six weeks.¹⁴ This timeline matters for treatment planning, because oncologists usually want bilirubin to normalize before starting chemotherapy. If bilirubin is not falling on schedule, that is a signal the stent may not be draining properly, and a repeat procedure may be needed.

Symptom relief tends to track the bilirubin drop. Jaundice fades over one to two weeks. Itching often improves sooner than the visible yellowing. Appetite and energy return more gradually, sometimes over several weeks.

Risks and Complications

Biliary stenting is generally safe, but it is not without risks. Short-term complications can include pancreatitis, bleeding, infection (cholangitis), and perforation of the duct. Post-procedure pancreatitis occurred in about 5% of patients in one large study of percutaneously placed metal stents, and stent placement in the common bile duct (as opposed to higher up) was the main risk factor.¹⁵ Most cases of post-procedure pancreatitis are mild and resolve with conservative care, but in rare instances it can be severe.

Cholangitis, an infection of the bile ducts, is perhaps the complication most important to watch for after you go home. The warning signs include fever, chills, worsening jaundice, and abdominal pain. If you develop these symptoms, you need urgent medical attention. In clinical studies, cholangitis was monitored at follow-up visits through symptoms and blood tests for bilirubin and liver enzymes, and it was considered a marker of stent dysfunction.¹⁶

When a Stent Stops Working

No biliary stent lasts forever. Over time, stents can become blocked by several mechanisms: sludge and biofilm building up inside, tumor growing through the mesh (ingrowth), or tumor growing over the ends of the stent (overgrowth).¹⁷ These failure modes are a well-known limitation of the technology, and high failure rates from ingrowth, overgrowth, and biofilm clogging remain an active area of research.¹⁸

Stent dysfunction typically announces itself through the same symptoms the stent was placed to fix: returning jaundice, fever, itching, or dark urine. When this happens, re-intervention is needed. Options include placing a second stent inside the first one (stent-in-stent), replacing the stent entirely, or using newer techniques like intraductal radiofrequency ablation to clear the blockage without needing an additional stent. In one small series, radiofrequency ablation restored patency in all nine patients treated, and some remained patent for many months before needing further treatment.¹⁹

How Stenting Affects Quality of Life

Beyond the laboratory numbers, the question that matters most is whether patients actually feel better. The evidence says yes, often meaningfully so. In a prospective study, patients who achieved at least a 33% drop in bilirubin after drainage showed significant improvements in social function and mental health at one month.²⁰ Patients with very high starting bilirubin (above 14 mg/dL) were less likely to see improvements in social functioning, which may reflect more advanced disease overall.

A randomized trial comparing metal and plastic stents found that patients with metal stents reported better physical and emotional functioning over time, along with less fatigue, nausea, and appetite loss. Both groups saw their overall health-related quality of life decline as the cancer progressed, but the decline was slower in the metal stent group.²¹ A separate study comparing endoscopic stenting to surgical bypass for palliation in metastatic pancreatic cancer found better quality-of-life scores in the stented group at both 30 and 60 days, with no difference in survival between the two approaches.²²

Stent Complications and Chemotherapy

For patients receiving palliative chemotherapy alongside a biliary stent, stent-related events can disrupt treatment in a serious way. In one study of patients with advanced pancreatobiliary tumors, 43% experienced a stent-related event during follow-up, most commonly cholangitis or stent obstruction. Among those who had a stent-related event, the consequences were significant: about a quarter experienced chemotherapy delays, 17% had to stop chemotherapy altogether, and 22% died in connection with the event.²³

This is one of the strongest arguments for choosing a metal stent over a plastic one in patients expected to receive ongoing chemotherapy. The longer patency of metal stents reduces the likelihood of a blockage event happening mid-treatment. It also underscores the importance of prompt medical attention if symptoms suggesting stent failure appear. Delaying evaluation when jaundice or fever return can cost precious treatment time.

Nutritional Recovery After Stenting

Bile duct obstruction does more than cause jaundice. Because bile is essential for digesting and absorbing dietary fats, patients with blocked ducts often lose weight, become malnourished, and develop inflammation. Restoring bile flow helps reverse this cycle, but recovery is not instantaneous.

A prospective study in elderly cholangiocarcinoma patients found that nutritional-inflammatory markers improved more in those who received metal stents compared to plastic stents over the first month. Improvements in nutritional indices predicted better survival outcomes, with each meaningful increase in a nutritional prognostic score associated with lower mortality. Conversely, patients with higher systemic inflammation markers at day 30 had worse outcomes. The takeaway is that stenting creates a window of opportunity for nutritional recovery, and making the most of that window with adequate caloric intake and attention to nutrition may genuinely matter for how things go afterward.

What Stent Costs Look Like

Metal stents cost more than plastic ones at the time of the initial procedure, sometimes several times more. This sticker shock leads some to wonder why metal is so strongly favored. The answer is in the total cost picture. A decision analysis found that the most economical strategy depended on how long the patient was expected to survive and the ratio of the metal stent’s price to the cost of the endoscopic procedure itself.²⁴ For patients surviving more than a couple of months, the repeat procedures required by plastic stents (each with its own sedation, hospital time, and potential complications) erode the initial savings. In one head-to-head study, patients surviving two to four months with plastic stents accumulated more re-interventions and longer hospital stays, bringing their total costs in line with or higher than the metal stent group.⁴

Living With a Biliary Stent

Day-to-day life with a biliary stent placed endoscopically is mostly unremarkable. The stent is entirely internal, so there is nothing visible on the outside and nothing to maintain at home. You can eat normally, and in fact eating becomes easier as bile flow resumes and fat absorption improves. If you have an external percutaneous drain, the situation is more hands-on: you will need to keep the exit site clean, flush the tube as instructed, and track the amount of bile draining into the collection bag. Hospital teams provide specific training before you go home in that scenario.

Regardless of stent type, the main thing to stay alert for is any return of the symptoms that prompted stenting in the first place. Worsening yellowing of the eyes, new fever, shaking chills, or darkening urine all warrant a call to your medical team the same day. Your oncologist and gastroenterologist will coordinate blood work on a schedule that makes sense for your treatment plan, and rising bilirubin levels on a routine lab draw may catch a problem before symptoms even appear.

Exercise and activity levels after stenting depend far more on the underlying cancer and its treatment than on the stent itself. Most patients are encouraged to return to their usual activity as soon as they feel up to it after the sedation wears off, typically within a day or two. There are no restrictions related to the stent on things like bending, lifting, or traveling, though your oncology team may have separate advice related to chemotherapy or other treatments.